Avalyn Pharma (NASDAQ:AVLN) Issues Quarterly Earnings Results

Avalyn Pharma (NASDAQ:AVLN) posted its earnings results on Wednesday. The company reported ($21.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45), Zacks reports.

Avalyn Pharma Stock Performance

Shares of Avalyn Pharma stock traded down $1.58 during trading on Wednesday, reaching $25.08. The stock had a trading volume of 4,104 shares, compared to its average volume of 342,418. Avalyn Pharma has a 52 week low of $24.15 and a 52 week high of $32.22.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a research report on Saturday, May 9th. Zacks Research raised Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Morgan Stanley started coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They set an “overweight” rating and a $53.00 target price on the stock. Evercore assumed coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price target on the stock. Finally, Guggenheim started coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $80.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $59.00.

Insider Buying and Selling

In other news, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were acquired at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the transaction, the insider owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 34.06% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jill Carroll bought 277,778 shares of the business’s stock in a transaction on Friday, May 1st. The stock was purchased at an average price of $18.00 per share, for a total transaction of $5,000,004.00. Following the purchase, the director directly owned 2,186,562 shares in the company, valued at approximately $39,358,116. This represents a 14.55% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.